Rui Yin
Department of Dermatology, Southwest Hospital, Third Military Medical University (Army Medical University) · Southwest Hospital, Third Military Medical University, Chongqing, 400038, China
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rui Yin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:45 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT06998875 · A Prospective Cohort Study on Primary Cutaneous AmyloidosisArmy Medical University, China · recruiting · Primary Cutaneous Amyloidosis · principal investigator
- N/ANCT06445699 · Photodynamic Therapy With Hydrogel Dressing for Chronic WoundsArmy Medical University, China · unknown · Photodynamic Therapy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:45 UTC. The ranking covers the 200 most relevant of 63 PubMed records, and a shared surname and initials can bring in a namesake. All 63 on PubMed
- 228 citationsRCR 11.8
- EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition.Cell Death Dis · 2014217 citationsRCR 6.5
- 174 citationsRCR 8.3
- Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.JAMA Oncol · 2023155 citationsRCR 13.3
- 73 citationsRCR 3.9
- 67 citationsRCR 4.6
- Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.Nat Commun · 202163 citationsRCR 2.8
- Low-dose topical 5-aminolevulinic acid photodynamic therapy in the treatment of different severity of acne vulgaris.Photodiagnosis Photodyn Ther · 201358 citationsRCR 3.2
- An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer.Clin Cancer Res · 202149 citationsRCR 2.2
- 46 citationsRCR 7.3